Arcellx, Inc. (ACLX) is making significant progress in the development of its lead CAR-T cell therapy, anitocabtagene Autoleucel (anito-cel), for the treatment of patients with relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback